Covaxin's 3rd booster shot shows positive responses

The study titled-Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial', found that 90% of the recipients of the booster dose had a "detectable neutralising antibody response" against the wild-type strain six months after the second Covid dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3FfKGak
via IFTTT